An anonymous reader quotes a report from NPR: The Environmental Protection Agency is proposing that nine PFAS, also known as "forever chemicals," be categorized as hazardous to human health. The EPA signed a proposal Wednesday that would deem the chemicals "hazardous constituents" under the Resource Conservation and Recovery Act. For the agency to consider a substance a hazardous constituent, it has to be toxic or cause cancer, genetic mutation or the malformations of an embryo. The full list of the nine substances can be found here.

The agency cited various studies in which forever chemicals were found to cause a litany of "toxic effects" in humans and animals, including, but not limited to cancer, a decreased response to vaccinations, high cholesterol, decrease in fertility in women, preeclampsia, thyroid disorders and asthma, the EPA said. Short for "per-and polyfluoroalkyl substances," PFAS cover thousands of man-made chemicals. PFAS are often used for manufacturing purposes, such as in nonstick cookware, adhesives, firefighting foam, turf and more. PFAS have been called "forever chemicals" because they break down very slowly and can accumulate in people, animals and the environment. Further reading: 'Forever Chemicals' Taint Nearly Half of US Tap Water, Study Estimates

An anonymous reader quotes a report from ScienceAlert: Peering into the jungle of microbes that live within us, researchers have stumbled across what seem to be an entire new class of virus-like objects. "It's insane," says University of North Carolina cell biologist Mark Peifer, who was not involved in the study, told Elizabeth Pennisi at Science Magazine. "The more we look, the more crazy things we see." These mysterious bits of genetic material have no detectable sequences or even structural similarities known to any other biological agents.

So Stanford University biologist Ivan Zheludev and colleagues argue their strange discovery may not be viruses at all, but instead an entirely new group of entities that may help bridge the ancient gap between the simplest genetic molecules and more complex viruses. "Obelisks comprise a class of diverse RNAs that have colonized, and gone unnoticed in, human, and global microbiomes," the researchers write in a preprint paper. Named after the highly-symmetrical, rod-like structures formed by its twisted lengths of RNA, the Obelisks' genetic sequences are only around 1,000 characters (nucleotides) in size. In fact, this brevity is likely one of the reasons we've failed to notice them previously.

In a study that has yet to be peer reviewed, Zheludev and team searched 5.4 million datasets of published genetic sequences and identified almost 30,000 different Obelisks. They appeared in about 10 percent of the human microbiomes the team examined. In one set of data, Obelisks turned up in 50 percent of the patients' oral samples. What's more, different types of Obelisks appear to be present in different areas of our bodies. "[This] supports the notion that Obelisks might include colonists of said human microbiomes," the researchers explain. They managed to isolate one type of host cell from our microbiome, the bacterium Streptococcus sanguinis -- a common human mouth microbe. The Obelisk in these microbes had a loop 1,137 nucleotides long. "While we don't know the 'hosts' of other Obelisks," write Zheludev and colleagues. "it is reasonable to assume that at least a fraction may be present in bacteria." The question of the Obelisks' source aside, all seem to include codes for a new class of protein the researchers have named Oblins. Zheludev and team couldn't identify any impact of the Obelisks on their bacterial hosts, or a means by which they could spread between cells. "These elements might not even be 'viral' in nature and might more closely resemble 'RNA plasmids,'" they conclude.

This research appears in the preprint server bioRxiv.

According to Neuralink founder Elon Musk, the first human received an implant from the brain-chip startup on Sunday and is recovering well. "Initial results show promising neuron spike detection," Musk added. Reuters reports: The U.S. Food and Drug Administration had given the company clearance last year to conduct its first trial to test its implant on humans. The startup's PRIME Study is a trial for its wireless brain-computer interface to evaluate the safety of the implant and surgical robot. The study will assess the functionality of the interface which enables people with quadriplegia, or paralysis of all four limbs, to control devices with their thoughts, according to the company's website.

In an announcement earlier today, Prime Minister Rishi Sunak said single-use vapes will be banned in Britain, with certain flavors restricted and regulations put in place around their packaging and displays. The New York Times reports: Mr. Sunak said that the ban, which is part of legislation that still has to be approved by Parliament, was intended to halt "one of the most worrying trends at the moment," before it becomes "endemic." "The long-term impacts of vaping are unknown and the nicotine within them can be highly addictive, so while vaping can be a useful tool to help smokers quit, marketing vapes to children is not acceptable," he said in a statement. Andrea Leadsom, Britain's health minister, said the measures were intended to make sure that vapes were aimed at adults who were quitting smoking, rather than children.

"Nicotine is highly addictive -- and so it is completely unacceptable that children are getting their hands on these products, many of which are undeniably designed to appeal to young people," she said in a statement. [...] While it is not illegal for people under 18 to smoke or vape in Britain, it is illegal for those products to be sold to them. By banning disposable vapes, and restricting the flavors and packaging of refillable vapes, the government hopes to make it far less likely that young people will experiment with e-cigarettes.

Andrew Joseph, writing for STAT News: There was something odd about these Alzheimer's cases. Part of it was the patients' presentations: Some didn't have the classic symptoms of the condition. But it was also that the patients were in their 40s and 50s, even their 30s, far younger than people who normally develop the disease. They didn't even have the known genetic mutations that can set people on the course for such early-onset Alzheimer's. But this small handful of patients did share a particular history. As children, they had received growth hormone taken from the brains of human cadavers, which used to be a treatment for a number of conditions that caused short stature.

Now, decades later, they were showing signs of Alzheimer's. In the interim, scientists had discovered that that type of hormone treatment they got could unwittingly transfer bits of protein into recipients' brains. In some cases, it had induced a fatal brain disease called Creutzfeldt-Jakob disease, or CJD -- a finding that led to the banning of the procedure 40 years ago. It seemed that it wasn't just the proteins behind CJD that could get transferred. As the scientific team treating the patients reported Monday in the journal Nature Medicine, the hormone transplant seeded the beta-amyloid protein that's a hallmark of Alzheimer's in some recipients' brains, which, decades later, propagated into disease-causing plaques. They are the first known cases of transmitted Alzheimer's disease, likely a scientific anomaly yet a finding that adds another wrinkle to ongoing arguments about what truly causes Alzheimer's. "It looks real that some of these people developed early-onset Alzheimer's because of that [hormone treatment]," said Ben Wolozin, an expert on neurodegenerative diseases at Boston University's medical school, who was not involved in the study.

"Exercising for 25 minutes a week, or less than four minutes a day, could help to bulk up our brains," reports the Washington Post, "and improve our ability to think as we grow older." A new study, which involved scanning the brains of more than 10,000 healthy men and women from ages 18 to 97, found that those who walked, swam, cycled or otherwise worked out moderately for 25 minutes a week had bigger brains than those who didn't, whatever their ages.

Bigger brains typically mean healthier brains. The differences were most pronounced in parts of the brain involved with thinking and memory, which often shrink as we age, contributing to risks for cognitive decline and dementia... The results have practical implications, too, about which types of exercise seem best for our brain health and how little of that exercise we may really need.
The article notes that the researchers used AI to assess brain scans from 10,125 "mostly healthy adults of all ages who'd come to the university medical center for diagnostic tests... A clear pattern quickly emerged." Men and women, of any age, who exercised for at least 25 minutes a week showed mostly greater brain volume than those who didn't. The differences weren't huge but were significant, said Cyrus A. Raji, an associate professor of radiology and neurology at Washington University in St. Louis, who led the new study, especially when the researchers looked deeper inside the organ. There, they found that exercisers possessed greater volume in every type of brain tissue, including gray matter, made up of neurons, and white matter, the brain's wiring infrastructure, which supports and connects the thinking cells. More granularly, the exercisers tended to have a larger hippocampus, a portion of the brain essential for memory and thinking. It usually shrinks and shrivels as we age, affecting our ability to reason and recall. They also showed larger frontal, parietal and occipital lobes, which, together, signal a healthy, robust brain...

Exactly how exercise might be altering brains is impossible to say from this study. But Raji and his colleagues believe exercise reduces inflammation in the brain and also encourages the release of various neurochemicals that promote the creation of new brain cells and blood vessels. In effect, exercise seems to help build and bank a "structural brain reserve," he said, a buffer of extra cells and matter that could protect us somewhat from the otherwise inevitable decline in brain size and function that occurs as we age. Our brains may still shrink and sputter over the years. But, if we exercise, this slow fall starts from a higher baseline...

When is cancer not cancer? It's an unexpected question that has stirred the world of cancer treatment in recent years, most notably now with prostate cancer. WSJ: A growing number of doctors are advocating what might seem like an unusual position: That low-grade prostate cancers that grow very slowly or not at all shouldn't be called cancer or carcinoma. The reason, they say, is that those words scare men, their families and sometimes even their doctors into seeking more aggressive treatment than patients need -- leaving men with debilitating side effects -- rather than pursuing a carefully monitored wait-and-see approach.

A name change wouldn't be unprecedented. Certain other forms of thyroid, cervical and bladder cancers have been reclassified, sometimes partly to avoid scaring people about cancers that are unlikely to spread. "The word 'cancer' engenders so much anxiety and fear," says Dr. Laura Esserman, a professor of surgery and radiology at the University of California, San Francisco and director of its Breast Care Center, who is advocating for a type of lower-risk breast cancer to be renamed. "Patients think if I don't do something tomorrow, this is going to kill me. In fact, that's not true."

An anonymous reader shares a report: The Dana-Farber Cancer Institute, an affiliate of Harvard Medical School, is seeking to retract six scientific studies and correct 31 others that were published by the institute's top researchers, including its CEO. The researchers are accused of manipulating data images with simple methods, primarily with copy-and-paste in image editing software, such as Adobe Photoshop. The accusations come from data sleuth Sholto David and colleagues on PubPeer, an online forum for researchers to discuss publications that has frequently served to spot dubious research and potential fraud. On January 2, David posted on his research integrity blog, For Better Science, a long list of potential data manipulation from DFCI researchers. The post highlighted many data figures that appear to contain pixel-for-pixel duplications. The allegedly manipulated images are of data such as Western blots, which are used to detect and visualize the presence of proteins in a complex mixture.

DFCI Research Integrity Officer Barrett Rollins told The Harvard Crimson that David had contacted DFCI with allegations of data manipulation in 57 DFCI-led studies. Rollins said that the institute is "committed to a culture of accountability and integrity," and that "every inquiry about research integrity is examined fully." The allegations are against: DFCI President and CEO Laurie Glimcher, Executive Vice President and COO William Hahn, Senior Vice President for Experimental Medicine Irene Ghobrial, and Harvard Medical School professor Kenneth Anderson. The Wall Street Journal noted that Rollins, the integrity officer, is also a co-author on two of the studies. He told the outlet he is recused from decisions involving those studies.

Testing a person's blood for a type of protein called phosphorylated tau, or p-tau, could be used to screen for Alzheimer's disease with "high accuracy," even before symptoms begin to show, a new study suggests. CNN: The study involved testing blood for a key biomarker of Alzheimer's called p-tau217, which increases at the same time as other damaging proteins -- beta amyloid and tau -- build up in the brains of people with the disease. Currently, to identify the buildup of beta amyloid and tau in the brain, patients undergo a brain scan or spinal tap, which often can be inaccessible and costly. But this simple blood test was found to be up to 96% accurate in identifying elevated levels of beta amyloid and up to 97% accurate in identifying tau, according to the study published Monday in the journal JAMA Neurology.

"What was impressive with these results is that the blood test was just as accurate as advanced testing like cerebrospinal fluid tests and brain scans at showing Alzheimer's disease pathology in the brain," Nicholas Ashton, a professor of neurochemistry at the University of Gothenburg in Sweden and one of the study's lead authors, said in an email. The study findings came as no surprise to Ashton, who added that the scientific community has known for several years that using blood tests to measure tau or other biomarkers has the potential to assess Alzheimer's disease risk. "Now we are close to these tests being prime-time and this study shows that," he said. Alzheimer's disease, a brain disorder that affects memory and thinking skills, is the most common type of dementia, according to the National Institutes of Health.

Gummy vitamin supplements have surged in popularity, with sales projected to double to $14 billion by 2027. However, experts warn that the candy-like taste and texture increase risks of overdosing, especially among children, as calls to Poison Control for melatonin overdoses have jumped 530% in a decade. Formulating vitamins into gummies also leads to faster nutrient degradation from heat, light and moisture than pills. Testing shows gummy vitamins often contain far more or less of ingredients than labels state. While some sweetness makes supplements appealing, gummies mimic candy too closely at the expense of safety and reliability. The Atlantic: A recent analysis of melatonin and CBD gummies yielded similar results: Some contained as much as 347 percent the amount of those substances stated on the label. Because the FDA generally does not regulate supplements as drugs, such wild variability is accepted in a way that it isn't for actual pharmaceuticals. (In 2020, the FDA granted the first-ever Investigational New Drug Application for a gummy medication, though no such product appears to have come to market.) "If you have something that you need a specific amount of every time you take it, gummies are not the way to go," says Pieter Cohen, a doctor at Cambridge Health Alliance, in Somerville, Massachusetts, and the lead author of the melatonin-CBD research. Taking too much of a supplement is generally not as dangerous as taking too much of a prescription drug, but, as Breuner noted, many supplements taken in sufficient excess can still be toxic. When I asked Cooperman what advice he had for people trying to navigate all of this, his answer was simple: "Don't buy a gummy."

Perhaps the rise of gummy supplements was inevitable. The supplement industry has become so big in part because it can promote its products as, say, boosting the immune system or supporting healthy bones, without subjecting them to the strict regulatory demands imposed on pharmaceuticals. Supplements blur the line between food and drug, and gummy supplements -- designed and marketed on the premise that healthy stuff can and should taste as good as candy -- only intensify that blurring. Cohen, for one, thinks the distinction is worth preserving. Calcium supplements should not go down as easy as Haribos. That may be a bitter pill to swallow, but not everything can taste like candy.

An anonymous reader quotes a report from ABC News: Doctors are now being encouraged to consider more blood testing for PFAS, also known as "forever chemicals," according to guidance released (PDF) by the Centers for Disease Control and Prevention (CDC). The federal agency is recommending providers have a discussion with their patients regarding consumer and environmental exposures to large levels of the chemicals, and if blood testing may be of benefit.

"This information is intended for individuals and communities around the country, who are concerned about exposure to PFAS to have productive conversations with their medical providers" Dr. Aaron Bernstein, Director of CDC's National Center for Environmental Health (NCEH) and the Agency for Toxic Substances and Disease Registry (ATSDR), told ABC News. "Over 90% of people in this country have been exposed to PFAS and many, many communities around the country there have been very high exposures. And we've learned more and more in recent years about how exposures to PFAS may increase risk for many disease" he added.

The new guidance advises providers to consider an individual's exposure history; the results of PFAS testing from a patient's water supply, food sources, or other exposures; and whether those results can inform regarding ways to reduce future exposures. Most Americans are exposed to PFAS through drinking water, according to Bernstein, who also notes that many municipal water agencies are already testing for PFAS, and those test results are typically publicly available. [...] While blood tests for PFAS may help guide exposure reduction or provide psychological relief to patients, such tests do not help identify the source of exposure, nor can they be directly linked to a health condition. There are also currently no approved medical treatments available to reduce PFAS in the body, according to the CDC. "A PFAS level is one piece of data that needs to be taken in a broader context. We need to understand the individual's health history, their family history, what other exposures they may have that might increase the risk of diseases that can also be associated with PFAS," Bernstein said.

"What is clear is that this is an evolving landscape [...] we are at a point in time that both the science around PFAS, the accessibility of testing, and what is being tested for is changing. We are committed at CDC to stay on top of it and update this information as needed."

The world's first routine vaccine programme against malaria has started in Cameroon, in a move projected to save thousands of children's lives across Africa. From a report: The symbolic first jab was given to a baby girl named Daniella at a health facility near Yaounde on Monday. Every year 600,000 people die of malaria in Africa, according to the World Health Organization (WHO). Children under five make up at least 80% of those deaths. Cameroon is offering the RTS,S vaccine free of charge to all infants up to the age of six months old.

Patients require a total of four doses. Health officials say these will be given at the same time as other routine childhood vaccines to make it easier for parents. It comes after successful pilot campaigns in Kenya, Ghana and Malawi - where the vaccine caused a 13% drop in malaria deaths in children of eligible age, says Unicef. The jab is known to be effective in at least 36% of cases, according to US researchers, meaning it could save over one in three lives. While the rollout is undoubtedly a relief and a life-saver, its relatively low efficacy rate means that it is not a "silver bullet," argues Willis Akhwale at End Malaria Council Kenya.

Slashdot reader quonset writes: After decades of study and testing, a potential vaccine for cancer may be on the horizon. Dr. Thomas Wagner, founder of Orbis Health Solutions, is using the body's own immune system to fight the disease, with each shot personalized to the patient, according to ABC News.
From the article: Typically, cancer cells evade a person's immune system because it is recognized as that person's cells. Wagner developed a tumor lysate particle only (TLPO) vaccine that uses a person's tumor cells to identify particular parts that are then presented back in the body using the vaccine in a way that can stimulate their immune system to gain the ability to detect these cancer cells like an infection, allowing the immune system to fight the cancer itself.

"People used to ask me the question, 'When will there be a cure for cancer?' And I've been doing this for 60 years and I could never answer that question," Wagner said. "Until recently, until the last three or four or five years." Wagner believes this type of cancer treatment could be a key to finding the long-awaited cure for cancer, all cancers, if paired with early detection.

Wagner's TLPO cancer vaccine has been tested in hundreds of patients with advanced forms of melanoma in Phase 2 clinical trials. The most recent data presented at an academic conference showed nearly 95% of people given only the vaccine were still alive three years after starting treatment and 64% were still disease-free. Among the most advanced forms of melanoma, disease-free survival after three years for people with stage III disease was 60% in the vaccine-only group, compared to about 39% in the placebo group. Disease-free survival for those with stage IV disease was about 68% in the vaccine-only group, and zero in the placebo group.

The most common side effects were redness or pain at the injection site, fever and fatigue after the injection – similar to other vaccines that stimulate an immune response.

Based on this data and other studies, the U.S. Food and Drug Administration has greenlit Wagner's vaccine to start a Phase 3 clinical trial. It will be a three-year endeavor with a goal to enroll 500 people and is planned to launch sometime this year, Riley Polk, president of Orbis Health Solutions, told WLOS, an ABC News affiliate in Asheville, North Carolina.
Polk's own father was told there were no treatment options left for his lung cancer, according to the article. That was more than 10 years ago, and "His father opted to try Wagner's cancer vaccine and lived 10 more years before dying from something unrelated to cancer." Polk gives ABC News this quote.

"You can tell me a lot of things, but you can't tell me [the vaccine] doesn't work."

"It's ridiculous just how virulent some of these bacteria get over time," says Dwayne Roach, assistant professor of bacteriophages, infectious disease and immunology at San Diego State University.

But now CNN says doctors are fighting multi-drug-resistant superbugs with "nature's oldest predators — tiny tripod-looking viruses called phages designed to find, attack and gobble up bacteria." The microscopic creatures have saved the lives of patients dying from superbug infections and are being used in clinical trials as a potential solution to the growing problem of antibiotic resistance...

In labs around the country, phage scientists are taking research and discovery to the next level... [Yale scientists] are busy mapping which phages and antibiotics are most symbiotic in the fight against a pathogen. Roach's San Diego State lab is investigating the body's immune response to phages while developing new phage purification techniques to prepare samples for intravenous use in patients. Currently, clinical trials are underway to test the effectiveness of phages against intractable urinary tract infections, chronic constipation, joint infections, diabetic foot ulcers, tonsillitis and the persistent, reoccurring infections that occur in patients with cystic fibrosis. The chronic infections common in cystic fibrosis are typically due to various strains of drug-resistant Pseudomonas aeruginosa — the same pathogen responsible for Horton's ear infection and the artificial tears outbreak.

A number of labs are developing libraries of phages, stockpiled with strains found in nature that are known to be effective against a particular pathogen. In Texas, a new facility is taking that a step further — speeding up evolution by creating phages in the lab. "Rather than just sourcing new phages from the environment, we have a bioreactor that in real time creates billions upon billions of phages," said Anthony Maresso, associate professor at Baylor College of Medicine in Houston. "Most of those phages won't be active against the drug-resistant bacteria, but at some point there will be a rare variant that has been trained, so to speak, to attack the resistant bacteria, and we'll add that to our arsenal," Maresso said. "It's a next-generation approach on phage libraries." Maresso's lab published a study last year on the treatment of 12 patients with phages customized to each patient's unique bacterial profile. It was a qualified success: The antibiotic-resistant bacteria in five patients were eradicated, while several more patients showed improvements.

"There's a lot of approaches right now that are happening in parallel," Roach said. "Do we engineer phages? Do we make a phage cocktail, and then how big is the cocktail? Is it two phages or 12 phages? Should phages be inhaled, applied topically or injected intravenously? There's a lot of work underway on exactly how to best do this...." Genetically engineering phages would allow scientists to target each person's unique mix of antibiotic-resistant pathogens instead of searching sewage, bogs, ponds, the bilge of boats and other prime breeding grounds for bacteria to find just the right phage for the job.

Along with phage libraries, genetic engineering is also a key to churning out phages in mass, to distribute on a wider scale. In Russia and the country of Georgia, where phage therapy has been used for decades, patients can buy phage cocktails off the shelf in pharmacies.

Private equity firms are increasingly buying hospitals across the US, and when they do, patients suffer, according to two separate reports. Specifically, the equity firms cut corners, slash services, lay off staff, lower quality of care, take on substantial debt, and reduce charity care, leading to lower ratings and more medical errors, the reports collectively find. ArsTechnica: Last week, the financial watchdog organization Private Equity Stakeholder Project (PESP) released a report delving into the state of two of the nation's largest hospital systems, Lifepoint and ScionHealth -- both owned by private equity firm Apollo Global Management. Through those two systems, Apollo runs 220 hospitals in 36 states, employing around 75,000 people. The report found that some of Apollo's hospitals were among the worst in their respective states, based on a ranking by The Lown Institute Hospital Index. The index ranks hospitals and health systems based on health equity, value, and outcomes, PESP notes. The hospitals also have dismal readmission rates and government rankings.

The Center for Medicare and Medicaid Services (CMS) ranks hospitals on a one- to five-star system, with the national average of 3.2 stars overall and about 30 percent of hospitals at two stars or below. Apollo's overall average is 2.8 stars, with nearly 40 percent of hospitals at two stars or below. The other report, a study published in JAMA late last month, found that the rate of serious medical errors and health complications increases among patients in the first few years after private equity firms take over. The study examined Medicare claims from 51 private equity-run hospitals and 259 matched control hospitals. Specifically, the study, led by researchers at Harvard University, found that patients admitted to private equity-owned hospitals had a 25 percent increase in developing hospital-acquired conditions compared with patients in the control hospitals. In private equity hospitals, patients experienced a 27 percent increase in falls, a 38 percent increase in central-line bloodstream infections (despite placing 16 percent fewer central lines than control hospitals), and surgical site infections doubled.

Cancer deaths in the United States are falling, with four million deaths prevented since 1991, according to the American Cancer Society's annual report. At the same time, the society reported that the number of new cancer cases had ticked up to more than two million in 2023, from 1.9 million in 2022. The New York Times: Cancer remains the second leading cause of death in the United States, after heart disease. Doctors believe that it is urgent to understand changes in the death rate, as well as changes in cancer diagnoses. The cancer society highlighted three chief factors in reduced cancer deaths: declines in smoking, early detection and greatly improved treatments. Breast cancer mortality is one area where treatment had a significant impact. In the 1980s and 1990s, metastatic breast cancer "was regarded as a death sentence," said Donald Berry, a statistician at the University of Texas MD Anderson Cancer Center and an author of a new paper on breast cancer with Sylvia K. Plevritis of Stanford University and other researchers (several authors of the paper reported receiving payments from companies involved in cancer therapies).

The paper, published Tuesday in JAMA, found that the death rate from breast cancer had fallen to 27 per 100,000 women in 2019 from 48 per 100,000 in 1975. That includes metastatic cancer, which counted for nearly 30 percent of the reduction in the breast cancer death rate. Breast cancer treatment has improved so much that it has become a bigger factor than screening in saving lives, said Ruth Etzioni, a biostatistician at the Fred Hutchinson Cancer Center. Death rates have even declined among women in their 40s, who generally did not have regular mammograms, said Dr. Mette Kalager, a professor of medicine at the University of Oslo and Oslo University Hospital, "indicating a substantial effect of treatment," she said.

An anonymous reader quotes a report from the New York Times: In an unmarked laboratory stationed between the campuses of Harvard and the Massachusetts Institute of Technology, a splinter group of scientists is hunting for the next billion-dollar drug. The group, bankrolled with $500 million from some of the wealthiest families in American business, has created a stir in the world of academia by dangling seven-figure paydays to lure highly credentialed university professors to a for-profit bounty hunt. Its self-described goal: to avoid the blockages and paperwork that slow down the traditional paths of scientific research at universities and pharmaceutical companies, and discover scores of new drugs (at first, for cancer and brain disease) that can be produced and sold quickly.

Braggadocio from start-ups is de rigueur, and plenty of ex-academics have started biotechnology companies, hoping to strike it rich on their one big discovery. This group, rather boastfully named Arena BioWorks, borrowing from a Teddy Roosevelt quote, doesn't have one singular idea, but it does have a big checkbook. "I'm not apologetic about being a capitalist, and that motivation from a team is not a bad thing," said the technology magnate Michael Dell, one of the group's big-money backers. Others include an heiress to the Subway sandwich fortune and an owner of the Boston Celtics. The wrinkle is that for decades, many drug discoveries have not just originated at colleges and universities, but also produced profits that helped fill their endowment coffers. The University of Pennsylvania, for one, has said it earned hundreds of millions of dollars for research into mRNA vaccines used against Covid-19. Under this model, any such windfall would remain private. [...]

The five billionaires backing Arena include Michael Chambers, a manufacturing titan and the wealthiest man in North Dakota, and Elisabeth DeLuca, the widow of a founder of the Subway chain. They have each put in $100 million and expect to double or triple their investment in later rounds. In confidential materials provided to investors and others, Arena describes itself as "a privately funded, fully independent, public good." Arena's backers said in interviews that they did not intend to entirely cut off their giving to universities. Duke turned down an offer from Mr. Pagliuca, an alumnus and board member, to set up part of the lab there. Mr. Dell, a major donor to the University of Texas hospital system in his hometown, Austin, leased space for a second Arena laboratory there. [Stuart Schreiber, a longtime Harvard-affiliated researcher who quit to be Arenaâ(TM)s lead scientist] said it would require years -- and billions of dollars in additional funding -- before the team would learn whether its model led to the production of any worthy drugs. "Is it going to be better or worse?" Dr. Schreiber said. "I don't know, but it's worth a shot."

In order to reach places like Alpha Centauri this century, we'll need to utilize gram-scale spacecraft that rely on directed-energy propulsion. To that end, NASA has selected the Swarming Proxima Centauri project for Phase I development as part of this year's NASA Innovative Advanced Concepts (NIAC) program. According to Universe Today, Swarming Proxima Centauri is "a collaborative effort between Space Initiatives Inc. and the Initiative for Interstellar Studies (i4is) led by Space Initiative's chief scientist Marshall Eubanks." From the report: According to Eubanks, traveling through interstellar space is a question of distance, energy, and speed. At a distance of 4.25 light-years (40 trillion km; 25 trillion mi) from the Solar System, even Proxima Centauri is unfathomably far away. To put it in perspective, the record for the farthest distance ever traveled by a spacecraft goes to the Voyager 1 space probe, which is currently more than 24 billion km (15 billion mi) from Earth. Using conventional methods, the probe accomplished a maximum speed of 61,500 km/h (38,215 mph) and has been traveling for more than 46 years straight.

In short, traveling at anything less than relativistic speed (a fraction of the speed of light) will make interstellar transits incredibly long and entirely impractical. Given the energy requirements this calls for, anything other than small spacecraft with a maximum mass of a few grams is feasible. [...] In contrast, concepts like Breakthrough Starshot and the Proxima Swarm consist of "inverting the rocket" -- i.e., instead of throwing stuff out, stuff is thrown at the spacecraft. Instead of heavy propellant, which constitutes the majority of conventional rockets, the energy source for a lightsail is photons (which have no mass and move at the speed of light). But as Eubanks indicated, this does not overcome the issue of energy, making it even more important that the spacecraft be as small as possible. "Bouncing photons off of a laser sail thus solves the speed-of-stuff problem," he said. "But the trouble is, there is not much momentum in a photon, so we need a lot of them. And given the power we are likely to have available, even a couple of decades from now, the thrust will be weak, so the mass of the probes needs to be very small -- grams, not tons."

Their proposal calls for a 100-gigawatt (GW) laser beamer boosting thousands of gram-scale space probes with laser sails to relativistic speed (~10-20% of light). They also proposed a series of terrestrial light buckets measuring a square kilometer (0.386 mi2) in diameter to catch the light signals from the probes once they are well on their way to reaching Proxima Centauri (and communications become more difficult). By their estimates, this mission concept could be ready for development around midcentury and could reach Proxima Centauri and its Earth-like exoplanet (Proxima b) by the third quarter of this century (2075 or after). [...] Eubanks and his colleagues hope that the development of a coherent swarm of robotic probes will have applications closer to home. Swarm robotics is a hot field of research today and is being investigated as a possible means of exploring Europa's interior ocean, digging underground cities on Mars, assembling large structures in space, and providing extreme weather tracking from Earth's orbit. Beyond space exploration and Earth observation, swarm robotics also has applications in medicine, additive manufacturing, environmental studies, global positioning and navigation, search and rescue, and more.

Researchers have designed an app to reduce the impact of tinnitus, an often debilitating condition that manifests via a ringing sound or perpetual buzzing. The Guardian reports: While there is no cure, there are a number of ways of managing the condition, including cognitive behavioural therapy (CBT). This helps people to reduce their emotional connection to the sound, allowing the brain to learn to tune it out. However, CBT can be expensive and difficult for people to access. Researchers have created an app, called MindEar, that provides CBT through a chatbot with other approaches such as sound therapy. "What we want to do is empower people to regain control," said Dr Fabrice Bardy, the first author of the study from the University of Auckland -- who has tinnitus.

Writing in the journal Frontiers in Audiology and Otology, Bardy and colleagues report how 28 people completed the study, 14 of whom were asked to use the app's virtual coach for 10 minutes a day for eight weeks. The other 14 participants were given similar instructions with four half-hour video calls with a clinical psychologist. The participants completed online questionnaires before the study and after the eight-week period. The results reveal six participants given the app alone, and nine who were also given video calls, showed a clinically significant decrease in the distress caused by tinnitus, with the extent of the benefit similar for both groups. After a further eight weeks, a total of nine participants in both groups reported such improvements.

In the coming months, Walmart will be expanding its drone delivery program in Texas to reach an 1.8 million additional households in the Dallas-Fort Worth area. The expansion will be completed within the year. The Verge reports: The retailer says its drone deliveries now cover 75 percent of the population in the Dallas-Fort Worth metro area, all thanks to partnerships with drone startups Wing and Zipline. Walmart launched its drone delivery program with Zipline and DroneUp in Arkansas in 2021 before expanding it to more states in 2022. The newly expanded service in Texas allows customers living within 10 miles of a participating Walmart to get items delivered to their homes via drone.

Since there is a weight limit, customers can only have smaller products like cold medicine, birthday candles, and even a carton of eggs delivered. Walmart says deliveries arrive in 30 minutes or less, with some reaching customers' doorsteps in as fast as 10 minutes. In 2023, Walmart partnered with Wing, which is owned by Google's parent company Alphabet, to deliver to 60,000 more homes in the Dallas-Fort Worth area from two different stores. But this marks its biggest expansion yet, adding 30 more towns and municipalities within the Texas metroplex. The program also now uses drones from both Wing and Zipline to make deliveries in the area, both of which are approved by the Federal Aviation Administration to fly drones "without a dedicated observer being able to see the drone at all times." You can check to see if deliveries are available for your address on the Wing and Zipline websites.